Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

Cancer

Volumn 118, Issue 24, 2012, Pages 6105-6109

  Cordes, Stefan ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Hayman, Suzanne R ^a   Buadi, Francis K ^a   Dingli, David ^a   Kumar, Shaji K ^a   Hogan, William J ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

amyloidosis complications; amyloidosis therapy; humans; immunoglobulin light chain; prognosis; stem cell transplantation; therapeutic use of alkylating agents

Indexed keywords

CHOLESTEROL; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PROTEIN;

ADULT; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEART VENTRICLE SEPTUM; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; SURVIVAL TIME; SURVIVOR; SYSTEMIC DISEASE; TREATMENT RESPONSE;

ADULT; AGED; AMYLOIDOSIS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84870699271     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27660     Document Type: Article

References (27)

1. Glenner GG, Terry WD, Isersky C,. Amyloidosis: its nature and pathogenesis. Semin Hematol. 1973; 10: 65-86.
2. Kyle RA, Gertz MA,. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995; 32: 45-59.
3. Falk RH, Comenzo RL, Skinner M,. The systemic amyloidoses. N Engl J Med. 1997; 337: 898-909.
4. Merlini G, Seldin DC, Gertz MA,. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011; 29: 1924-1933.
5. Merlini G, Bellotti V,. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349: 583-596.
6. Schultz CP,. Illuminating folding intermediates. Nat Struct Biol. 2000; 7: 7-10.
7. Jayasinghe SA, Langen R,. Membrane interaction of islet amyloid polypeptide. Biochim Biophys Acta. 2007; 1768: 2002-2009.
8. Murphy RM,. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. Biochim Biophys Acta. 2007; 1768: 1923-1934.
9. Engel MFM, Khemtemourian L, Kleijer CC, et al. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc Natl Acad Sci USA. 2008; 105: 6033-6038.
10. Friedman R, Pellarin R, Caflisch A,. Amyloid aggregation on lipid bilayers and its impact on membrane permeability. J Mol Biol. 2009; 387: 407-415.
11. Skinner M, Anderson JJ, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996; 100: 290-298.
12. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997; 336: 1202-1207.
13. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-2520.
14. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC,. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007; 110: 3561-3563.
15. Palladini G, Merlini G,. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol. 2011; 23: 214-220.
16. Palladini G, Dispenzieri A, Gertz MAA, et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood. 2010; 116: 586-587.
17. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011; 46: 970-975.
18. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G,. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Tours, France. April 18-22, 2004, Am J. Hematol. 2005; 79: 319-328.
19. Andersen PK, Gill RD,. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982; 10: 1100-1120.
20. Therneau TM, Grambsch PM, Fleming TR,. Martingale-based residuals for survival models. Biometrika. 1990; 77: 147-160.
21. Tsiatis AA,. A large sample study of Cox's regression model. Ann Stat. 1981; 9: 93-108.
22. Kramer CY,. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 1956: 12: 309-310.
23. Herrmann SM, Gertz MA, Stegall MD, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011; 26: 2032-2036.
24. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003; 361: 1787-1789.
25. Caccialanza R, Palladini G, Klersy C, et al. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr. 2006; 83: 350-354.
26. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004; 34: 1025-1031.
27. Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011; 86: 251-255.